Heart transplant patients get new weapon against hidden artery damage
NCT ID NCT03537742
First seen Apr 19, 2026 · Last updated Jun 18, 2026 · Updated 6 times
Summary
This study tested the drug alirocumab in 114 heart transplant recipients to see if it safely reduces plaque buildup in the new heart's arteries. The drug targets a protein called PCSK9 to lower harmful cholesterol. Researchers measured changes in artery plaque using ultrasound at the start and one year later. The goal was to prevent a condition called cardiac allograft vasculopathy, which can damage the transplanted heart over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VASCULOPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Stanford University
Stanford, California, 94305, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.